Three phase I clinical trials and a recently reported phase II clinical trial of endostatin in patients with advanced neuroendocrine tumours have not demonstrated anti-tumour activity (Eder et al, 2002; Herbst et al, 2002; Thomas et al, 2003; Kulke et al, 2006). This evidence concerns the gene COL18A1 and neoplasm.